Literature DB >> 15591639

Anxiolytic- and antidepressant-like effects of 7-OH-DPAT, preferential dopamine D3 receptor agonist, in rats.

Z Rogóz1, G Skuza, A Kłlodzińska.   

Abstract

The aim of the present study was to examine a potential anxiolytic- and antidepressant-like action of (+)-7-hydroxy-2-(di-n-propylamino)tetralin hydrobromide (7-OH-DPAT), a preferential dopamine D(3) receptor agonist, and N-{4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl}-2-naphthylcarboxamide (BP 897), a partial dopamine D(3) receptor agonist, in male Wistar rats. Diazepam or imipramine were used as reference compounds. The anxiolytic-like effect of those drugs was tested in the elevated plus-maze test. The antidepressant-like effect was estimated using the forced swimming test. The obtained results showed that 7-OH-DPAT at low doses and BP 897 (like diazepam) induced anxiolytic-like effects in the elevated plus-maze test. 7-OH-DPAT, BP 897 and diazepam, tested at the doses effective in the model of anxiolytic-like actions, did not affect motor coordination. Moreover, 7-OH-DPAT at higher doses, like imipramine, showed antidepressant-like effect, significantly reducing immobility time in the forced swimming test. Combined treatment with 7-OH-DPAT and imipramine induced a stronger effect in Porsolt's test than administration of either drug alone, but did not increase the locomotor activity. In contrast, BP 897 was inactive in the forced swimming test when given alone but it potentiated the antidepressant-like effect of imipramine. These data suggest that preferential D(3) receptor agonists may play a role in the therapy of anxiety and/or depression, however, further studies are necessary to elucidate the mechanism of these actions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15591639

Source DB:  PubMed          Journal:  Pol J Pharmacol        ISSN: 1230-6002


  8 in total

Review 1.  Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?

Authors:  Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu
Journal:  Ageing Res Rev       Date:  2019-11-22       Impact factor: 10.895

2.  Cabergoline, a dopamine receptor agonist, has an antidepressant-like property and enhances brain-derived neurotrophic factor signaling.

Authors:  Shuichi Chiba; Tadahiro Numakawa; Midori Ninomiya; Hyung Shin Yoon; Hiroshi Kunugi
Journal:  Psychopharmacology (Berl)       Date:  2010-06-05       Impact factor: 4.530

3.  Effects of bupropion on the forced swim test and release of dopamine in the nucleus accumbens in ACTH-treated rats.

Authors:  Yoshihisa Kitamura; Takahiko Yagi; Kouhei Kitagawa; Kazuaki Shinomiya; Hiromu Kawasaki; Masato Asanuma; Yutaka Gomita
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-06-06       Impact factor: 3.000

Review 4.  Dopamine Receptors: Is It Possible to Become a Therapeutic Target for Depression?

Authors:  Fangyi Zhao; Ziqian Cheng; Jingjing Piao; Ranji Cui; Bingjin Li
Journal:  Front Pharmacol       Date:  2022-08-17       Impact factor: 5.988

5.  Effects of pramipexole on the duration of immobility during the forced swim test in normal and ACTH-treated rats.

Authors:  Kouhei Kitagawa; Yoshihisa Kitamura; Toshiaki Miyazaki; Junya Miyaoka; Hiromu Kawasaki; Masato Asanuma; Toshiaki Sendo; Yutaka Gomita
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-03-10       Impact factor: 3.000

6.  Synthesis and anticancer activity of some novel tetralin-6-yl-pyrazoline, 2-thioxopyrimidine, 2-oxopyridine, 2-thioxo-pyridine and 2-iminopyridine derivatives.

Authors:  Ebtehal S Al-Abdullah
Journal:  Molecules       Date:  2011-04-20       Impact factor: 4.411

Review 7.  Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders.

Authors:  Béla Kiss; István Laszlovszky; Balázs Krámos; András Visegrády; Amrita Bobok; György Lévay; Balázs Lendvai; Viktor Román
Journal:  Biomolecules       Date:  2021-01-14

8.  Dopamine D3 Receptor Mediates Preadolescent Stress-Induced Adult Psychiatric Disorders.

Authors:  Joon H Seo; Eldo V Kuzhikandathil
Journal:  PLoS One       Date:  2015-11-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.